The high number of premium-priced NSCLC therapies and the large number of NSCLC patients result in significant financial burden for payers. These costs are set to increase with the approval of additional therapies, such as AstraZeneca’s Imfinzi for unresectable stage III NSCLC, and with label expansions of existing treatments, such as AstraZeneca’s Tagrisso in first-line EGFR–mutation-positive NSCLC. To control the rising costs of NSCLC treatment, payers employ extensive utilization management strategies. Presenting data from surveys of 31 MCOs and 102 oncologists, this access and reimbursement content analyzes the reimbursement environment for eight of the major new therapies for metastatic NSCLC, and how MCO formulary decisions and utilization controls on both the pharmacy benefit and medical benefit affect prescribing by surveyed oncologists.
Access & Reimbursement provides in-depth insight regarding the impact of payer policy on physician prescribing behavior so you can build your market access strategy and optimize your brand positioning.
Markets covered: United States
Key drugs covered: Opdivo, Keytruda, Tecentriq, Imfinzi, Alecensa, Xalkori, Tagrisso, Tarceva.